Tserenpuntsag Boldpioner, Kołacińska Agnieszka, Jabłonowska Elzbieta
Klinika Chorób Zakaźnych i Hepatologii UM w Lodzi.
Przegl Epidemiol. 2007;61(3):529-34.
HIV infected subjects are at increased risk of developing cancer and the risk seems to be directly associated with the level of immunodeficiency. Kaposi's sarcoma, Non-Hodgkin's lymphoma (ARL) and invasive cervical cancer are the most common AIDS-defining malignancies. HAART widely used since 1996 changed the natural process of HIV infection by aggressively suppressing viral replication and progress of HIV disease. It significantly reduced the incidence of AIDS associated events and deaths and even changed treatment regimens ofAIDS associated cancers. With the immune restoration afforded by HAART, patients better responded to cancer treatment. There are data demonstrating that HAART regimens alone lead to remission of Kaposi's sarcoma. HAART allows the use of standard-dose chemotherapies for NON-Hodgkin lymphoma in HIV infected pacients and same treatment regimen for invasive cervical cancer in infected patients as non-infected patients.
感染HIV的受试者患癌症的风险增加,且这种风险似乎与免疫缺陷程度直接相关。卡波西肉瘤、非霍奇金淋巴瘤(ARL)和浸润性宫颈癌是最常见的艾滋病定义性恶性肿瘤。自1996年以来广泛使用的高效抗逆转录病毒治疗(HAART)通过积极抑制病毒复制和HIV疾病进展改变了HIV感染的自然进程。它显著降低了与艾滋病相关事件和死亡的发生率,甚至改变了艾滋病相关癌症的治疗方案。随着HAART带来的免疫恢复,患者对癌症治疗的反应更好。有数据表明,仅HAART方案就能使卡波西肉瘤缓解。HAART允许在感染HIV的患者中使用标准剂量化疗治疗非霍奇金淋巴瘤,并且感染患者的浸润性宫颈癌治疗方案与未感染患者相同。